- Home
- CYD vs MREO Comparison
CYD vs MREO Comparison
Compare CYD & MREO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CYD | MREO |
|---|---|---|
| Founded | 1951 | 2015 |
| Country | Singapore | United Kingdom |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.7B | 67.5M |
| IPO Year | 1998 | 2017 |
Fundamental Metrics
Financial Performance| Metric | CYD | MREO |
|---|---|---|
| Price | $40.11 | $0.35 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 1 | 5 |
| Target Price | ★ $60.00 | $1.50 |
| AVG Volume (30 Days) | 251.3K | ★ 1.4M |
| Earning Date | 02-24-2026 | 03-19-2026 |
| Dividend Yield | ★ 1.30% | N/A |
| EPS Growth | N/A | ★ 16.67 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $500,000.00 |
| Revenue This Year | $15.11 | $6,756.00 |
| Revenue Next Year | $8.67 | $38.65 |
| P/E Ratio | $32.71 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $12.66 | $0.20 |
| 52 Week High | $56.55 | $2.94 |
Technical Indicators
Market Signals| Indicator | CYD | MREO |
|---|---|---|
| Relative Strength Index (RSI) | 40.34 | 38.00 |
| Support Level | $34.58 | $0.35 |
| Resistance Level | $41.24 | $0.42 |
| Average True Range (ATR) | 1.92 | 0.03 |
| MACD | -0.15 | 0.00 |
| Stochastic Oscillator | 43.91 | 32.16 |
Price Performance
Historical ComparisonAbout CYD China Yuchai International Limited
China Yuchai International Ltd is a Bermuda holding company that is a subsidiary of Singapore-based Hong Leong Asia. China Yuchai International operates through its majority-owned subsidiary Guangxi Yuchai Machinery Company, a China-based company that manufactures, assembles, and distributes diesel engines for various vehicles including trucks, buses, and cars, as well as construction and agricultural, marine, and power-generation equipment. It generates the majority of its sales from the Chinese market.
About MREO Mereo BioPharma Group plc
Mereo BioPharma Group PLC is a United Kingdom (U.K.) based biopharmaceutical company focused on the development of therapeutics for rare diseases. The company has developed a portfolio of late-stage clinical product candidates, and its two rare disease product candidates are setrusumab for the treatment of osteogenesis imperfecta (OI) and alvelestat primarily for the treatment of severe alpha-1 antitrypsin deficiency-associated lung disease (AATD-LD).